Clinical trials: Hepatic Chemotherapy
Hepatocellular Carcinoma
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
This study is a prospective, randomized controlled, multicenter clinical study. The purpose of this study is to explore the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with second-line regorafenib…
- Trial name
- NCT05233358
- Testing
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib
- Volunteers
- 176 people
- Sponsor
- The Central Hospital of Lishui City
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Colorectal Cancer, Metastatic Cancer
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
The purpose of this study is to find the highest dose that can be given safely to people who have had liver disease resected. This is a Phase I study.
- Trial name
- NCT00059930
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms, Floxuridine
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The goal of this randomized clinical trial is to investigate induction treatment with Hepatic Arterial Infusion Pump therapy combined with systemic therapy (HAIP-SYST) in chemotherapy-naive patients with unresectable colorectal…
- Conditions
- Colorectal Neoplasms, Floxuridine, Liver Metastases, Vascular Access Device
- Trial name
- PUMP-IT RCT (NCT06857773)
- Testing
- Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy, Hepatic arterial infusion pump (HAIP), Systemic therapy (standard of care)
- Where
- Netherlands
- Volunteers
- 306 people
- Sponsor
- The Netherlands Cancer Institute
HepatoCellular Carcinoma
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC…
- Trial name
- NCT02973685
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
- Trial name
- FRONT-1 (NCT05532319)
- Testing
- HAIC sequential TAE combined with lenvatinib and tislelizumab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Guangxi Medical University
Liver Cancer
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Purpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients…
- Trial name
- NCT07685535
- Testing
- DEB-TACE, Toripalimab, Lenvatinib
- Volunteers
- 29 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Liver Metastases
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
Tislelizumab is an anti-PD-1 monoclonal antibody with high binding affinity for PD-1 and with minimized Fcγ receptor binding on macrophages. Regorafenib has been approved in mCRC by CFDA.
- Trial name
- NCT05877001
- Testing
- Tislelizumab, Regorafenib, HAIC
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Immune checkpoint inhibitors (ICIs) plus antiangiogenic agents can achieve better efficacy than sorafenib in the treatment of hepatocellular carcinoma (HCC) within a certain period of time, but more than half of the patients are…
- Trial name
- NCT05718492
- Testing
- digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Trial name
- NCT05863195
- Testing
- Bevacizumab, Capecitabine, Cetuximab
- Where
- 62 sites in United States
- Volunteers
- 408 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Resectable Hepatic Metastases of Colorectal Cancer
Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer
The immune response at primary tumor has a major role in the prognosis of colorectal cancer (CRC). Some studies suggest a prognosis value of cytotoxic T cell and memory T cells at primary tumor greater than tumoral stage.
- Trial name
- METAHEP (NCT01673607)
- Testing
- Biopsie liver
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Poitiers University Hospital
Advanced Hepatocellular Carcinoma (HCC)
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely applied and shows good efficacy in advanced hepatocellular carcinoma (HCC). Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity in the treatment of…
- Trial name
- NCT05862181
- Testing
- DEB-TACE plus HAIC or HAIC alone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Wilson Disease
Establishment of Human Cellular Disease Models for Wilson Disease
Establishment of human cellular disease models for Wilson disease for an individualized therapy develop-ment having the capacity to address both hepatic and neurologic forms of the disease
- Trial name
- IPSWILSON (NCT03867526)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05400902
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Binkui Li
HCC
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially…
- Trial name
- NCT07119931
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Liver cancer is a highly lethal malignancy and has become increasingly important in western countries. The management of liver cancer is complex.
- Trial name
- ALICE (NCT06904170)
- Testing
- Durvalumab Plus Tremelimumab, HAIC (GEMOX)
- Where
- 11 sites in France
- Volunteers
- 196 people
- Sponsor
- UNICANCER
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Melanoma, Uveal Neoplasms
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in patients with isolated liver metastases from uveal…
- Trial name
- SCANDIUM (NCT01785316)
- Testing
- IHP
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Vastra Gotaland Region